申请人:Kissei Pharmaceutical Co., Ltd.
公开号:EP2460791A1
公开(公告)日:2012-06-06
A compound (I) of the present invention, which has an EP1 receptor antagonism:
[wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R3represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
具有 EP1 受体拮抗作用的本发明化合物 (I):
[其中 A 代表苯环或类似物;Y1 代表 C1-6 亚烷基;Y2 代表单键或类似物;R1 代表氢原子、C1-6 烷基或类似物;R2 代表可能具有取代基的苯基、可能具有取代基的 5 元芳香杂环、可能具有取代基的 6 元芳香杂环或类似物;R3代表卤素原子、C1-6烷氧基或类似基团;R4代表氢原子或类似基团;R5代表氢原子或类似基团]或其药学上可接受的盐。此外,本发明的化合物(I)可用作治疗或预防 LUTS,特别是 OABs 的各种症状的制剂。